key: cord-0756467-dtr9muza
authors: Wang, Guyi; Wu, Shangjie; Wu, Chenfang; Zhang, Quan; Wu, Fang; Yu, Bo; Zhang, Siye; Wu, Chao; Wu, Guobao; Zhong, Yanjun
title: Association between non‐alcoholic fatty liver disease with the susceptibility and outcome of COVID‐19: A retrospective study
date: 2021-11-10
journal: J Cell Mol Med
DOI: 10.1111/jcmm.17042
sha: 98d13e34211f9c88482d85acd431272e567b4669
doc_id: 756467
cord_uid: dtr9muza

This study aims to evaluate the effect of non‐alcoholic fatty liver disease (NAFLD) on the susceptibility and consequences of coronavirus disease 2019 (COVID‐19). We retrospectively collected data from 218 adult COVID‐19 patients who showed no evidence of excessive alcohol consumption and underwent abdominal ultrasound examinations. Of these patients, 39.4% patients had been diagnosed with NAFLD, which indicates a much higher prevalence of NAFLD than that reported in the general population. Significantly elevated white blood cell count (p = 0.008), alanine aminotransferase (p = 0.000), aspartate aminotransferase (p = 0.006) and C reactive protein (p = 0.012) were found in the patients with NAFLD. These patients also had significantly higher proportions of hypertension (p = 0.006) and diabetes (p = 0.049) than the non‐NAFLD cases. No significant differences existed in the severity, mortality, viral shedding time and length of hospital stay between patients with or without NAFLD in the sample population. However, subgroup analyses found that in patients with normal body mass index (BMI), NAFLD sufferers were more likely to experience a severe event (30.0% vs 11.5%, p = 0.021). Kaplan‐Meier curve (log‐rank p = 0.017) and Cox regression (HR = 3.26, 95% CI: 1.17–9.04, p = 0.023) analyses confirmed that before and after adjusting for gender, age and comorbidities, NAFLD patients with normal BMI had a higher incidence of suffering severe events. People with NAFLD may have a higher proportion of COVID‐19. NAFLD may be correlated with the severity of COVID‐19 patients in the normal BMI group.

COVID-19. 9 Liver impairment has been reported in up to 50% of patients with COVID-19, and more than 60% of severe cases. 10 Histological examination in the liver of a COVID-19 patient showed moderate micro-vesicular steatosis and mild lobular and portal activity. 11 However, the causes of liver injury in COVID-19 cases and the effects of liver-related comorbidities on the susceptibility and outcomes of COVID-19 remain unclear.

Non-alcoholic fatty liver disease (NAFLD) is an acquired metabolic stress-related liver disorder, with an overall global prevalence of about 25%. 12 The incidence of NAFLD in China is rising rapidly, from about 23.8% in the early 2000s to about 32.9% in 2018. [12] [13] [14] [15] often coexists with hyperlipidaemia and/or obesity. [16] [17] [18] [19] Therefore, this study aims to evaluate the relationship between NAFLD and COVID-19 using a retrospective cohort of Chinese individuals diagnosed with COVID-19.

The study protocol was subject to approval by the institutional ethics board of the Second Xiangya Hospital of Central South University (No. 2020001) . We retrospectively collected data from a cohort of subjects who had laboratory-confirmed were patients in the Public Health Treatment Center of Changsha, China, before 14 March 2020. Fatty liver was diagnosed based on the ultrasound parameters (such as parenchymal brightness, deep beam attenuation and liver-to-kidney contrast) by abdominal ultrasonography with a 3.5-MHz transducer (S9, SonoScape, China).

Ultrasonography was performed by the experienced radiologists for medical indications in the Public Health Treatment Center of Changsha, China. We used the following criteria to diagnose NAFLD: (1) The presence of fatty liver; (2) The absence of excessive alcohol consumption (average alcohol intake ≥30 g/day for men and ≥20 g/ day for women).

Two authors carefully collected and reviewed the individual medical records of the patients. Detailed information on demographic data, body mass index (BMI), underlying comorbidities, medical history, symptoms, laboratory parameters, chest computed tomographic (CT) scans and outcomes were recorded. For BMI data, the medical records of 18 patients did not include height and weight.

The primary endpoint of this study was a severe event, which was defined using the following criteria: (1) respiratory rate ≥30 breaths/min;

(2) oxygen saturation <93%; (3) PaO2/FiO2 ≤ 300 mmHg; (4) lung lesions progressed to greater than 50% within 24-48 hours; (5) mechanical ventilation was implemented; (6) shock; (7) combined with other organ failures, required intensive care. 20 Secondary endpoints included the mortality rate, virus shedding time and length of hospital stay.

Because the continuous variables in this study were non-normal distributed, we used the Fisher's exact test (χ2 test) and Mann-Whitney F I G U R E 1 Flow chart of the study population test to compare the differences between the categorical variables and the continuous variables, separately. The Kaplan-Meier (KM) method and the log-rank test were applied to assess the association between NAFLD and the outcomes. Cox regression was conducted to further evaluate the effect of NAFLD after adjusting for other risk factors. All analyses were performed using IBM SPSS Statistics version 26.0 software.

In this study, we retrospectively collected the data of 230 adult patients who had contracted laboratory-confirmed COVID-19 before [11.7-29.3] , p = 0.000) and higher proportions of hypertension (23.3% vs 9.1%, p = 0.004) and diabetes (10.5% vs 3.8%, p = 0.049). However, no significant differences were found in other comorbidities (including cardiovascular disease and chronic liver disease) and common COVID-19 symptoms (including fever, cough, fatigue and expectoration). Two of the patients (1.5%) died, while the remaining 216 patients were discharged before 14 March 2020 ( Table 1 ).

The two patients who died did not suffer from NAFLD.

In terms of laboratory findings, considerably higher levels of white blood cells (5.0 x 10 9 /L [1.9-13.4] were detected in the patients with NAFLD than in those without NAFLD. Meanwhile, the proportions of procalcitonin positive subjects (36.0% vs 22.0%, p = 0.023) and the incidence of ground-glass opacity obtained from chest CTs (58.1% vs 37.9%, p = 0.003) were significantly higher in the NAFLD group than in the non-NAFLD group ( Table 1 ). This may suggest that patients with NAFLD had a higher inflammatory response to SARS-CoV-2 infection and a higher incidence of liver injury. Moreover, significantly differences were observed in the serum levels of lipid metabolism, including total cholesterol (3.9 mg/dL [2.3-6.9 ] vs 3.6 mg/dL [1.9-6.4] , p = 0.018), lowdensity lipoprotein (LDL) cholesterol (2.7 mg/dL [1.5-5.9] vs 18 days , p = 0.165), length of hospital stay (15 days [5-41] vs 16 days , p = 0.407) and mortality (0% vs 1.5%, p = 0.251).

Next, to investigate whether the effect of NAFLD on the outcomes of COVID-19 patients was dependent on gender, age, BMI or comorbidities, we divided our patients into subgroups according to these factors. We found that in patients with normal BMI (18.5 ≤ BMI <24 kg/m 2 ), NAFLD patients were more likely to develop severe events than those without NAFLD (30.0% vs 11.5%, p = 0.021).

However, no significant differences were found in patients with low (< 18.5 kg/m 2 ) or high (≥ 24 kg/m 2 ) BMI values ( Table 2) (Table 3) . Thus, a KM analysis was performed and confirmed that NAFLD patients were more likely to experience a severe event (log-rank p = 0.017; Figure 2 ). After adjusting for gender, age, hypertension, cardiovascular disease, diabetes and chronic liver disease, NAFLD is significantly correlated with the severity of COVID-19 (HR =3.26, 95% CI: 1.17-9.04, p = 0.023; Table 4 ) in the normal BMI group.

Moreover, the results showed that in non-elderly patients (< 60 years), those with NAFLD had a higher incidence of severe events (21.2% vs 10.5%, p = 0.036; Table 2 ). Subsequently, a KM analysis confirmed that non-elderly NAFLD patients had a significantly elevated risk of suffering a severe event compared with those without NAFLD (log-rank p = 0.035; Figure S1 ). However, after adjusting for gender, hypertension, cardiovascular disease, diabetes and chronic liver disease, NAFLD had no significant influence on the likelihood of the severe events in non-elderly patients (HR =1.79, 95% CI: 0.72-4.44, p = 0.208; Table S2 ).

No significant effects of NAFLD were found on the virus shedding time or length of hospital stay in the patient cohort. Thus, we performed subgroup analyses according to gender, age, BMI and the common comorbidities. Results showed that in elderly patients, the virus shedding time was significantly lower in NAFLD patients than in non-NAFLD individuals (16 days [4-38] vs 23 days , p = 0.011; Table 2 ). In terms of laboratory findings among elderly patients, alanine aminotransferase was conspicuously higher in patients with NAFLD, compared to those without (25.0 U/L [12.8-58 .1] vs 15.6 U/L [4.9-69.4] , p = 0.002; Table S1 ).

This study investigated the susceptibility of patients with NAFLD to SARS-CoV-2 and the association between NAFLD and outcomes of COVID-19. We found that individuals with NAFLD may be more susceptible to SARS-CoV-2 than those without NAFLD. In patients with normal BMI, those with NAFLD who were infected by COVID-19 may have a higher proportion of developing severe diseases than other patients.

In our study, 39.4% of the COVID-19 patients we investigated had NAFLD, which is significantly higher than the rate reported in the general population. [12] [13] [14] [15] This finding is consistent with another study that was done in China. 21 It suggests that NAFLD sufferers generally seem to be more susceptible to SARS-CoV-2 infection than people without NAFLD. Although the reason for this is not yet known, immune system disorders in NALFD may be an important cause, such as a decrease in CD4 + T cells and abnormal macrophage function. 22, 23 NAFLD often coexists with hyperlipidaemia and obesity. 17, 18 People with NAFLD usually have a high incidence of hypertension, diabetes and cardiovascular disease. All of these conditions have been demonstrated to be independent risk factors of COVID-19. 24 NAFLD (n = 86) 17.5 (3-47) 18.5 0.138 16.5 (11-45) 18 (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) 35 (22) (23) (24) (25) (26) (27) (28) (29) 0.114 22 (19) (20) (21) (22) (23) (24) (25) (26) (27) 24.5 (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) 24 0.537 13 (9-27) 22 In this study, compared with the non-NAFLD patients, the proportions of hypertension and diabetes were also significantly higher in the NAFLD group, which is similar to the conclusions of previous studies.

Despite no evidence of increased liver uptake of SARS-CoV-2 in NAFLD patients, 25 in our study, the COVID-19 cases with NAFLD had higher levels of alanine aminotransferase and aspartate aminotransferase than the other patients. Moreover, patients with abnormal liver tests are at a higher risk of developing to the severe events. 26 It has been reported that patients with NAFLD have a higher risk of disease progression, 21 while NAFLD patients with an increased fibrosis-4 index and NAFLD fibrosis score are at a higher risk of suffering a severe event due to However, the influence of NAFLD on the COVID-19 in subgroups of age, gender, BMI and comorbidities remains unclear.

The prevalence and severity of NAFLD vary between different age groups. 15, 28 A large sample study in China found that, compared to non-elderly adults (18-59 years) , the elderly (≥ 60 years) showed a lower overall prevalence of NAFLD, but a higher proportion of NAFLD accompanied with diabetes, hypertension and hyperlipidaemia. 29 Elderly NAFLD patients are more likely to develop nonalcoholic steatohepatitis and fibrosis than non-elderly patients. 30 Moreover, NAFLD is considered to be associated with increased mortality in elderly people. 31 Interestingly, in the non-elderly group The susceptibility to COVID-19 of NAFLD sufferers increases linearly with BMI. It increases 5-to 10-fold in obese patients and by a factor of 10-to 14-fold in the morbidly obese. 32 However, a significant proportion of NAFLD patients have relatively normal BMI, and it has been reported that obese NAFLD has different clinical characteristics from non-obese NAFLD. 33 Therefore, in this study,

we performed a subgroup analysis on BMI and found that in patients with a normal BMI (18.5-24 kg/m 2 ), NAFLD was associated with an increased risk of severe disease. However, we did not find similar results in patients with higher and lower BMI, which may be related to their different metabolic states. This is an interesting result, but well-designed studies with larger sample sizes are required to investigate this assumption.

This study contains several limitations. Firstly, we analysed the effect of NAFLD on the susceptibility and outcome of COVID-19 in one of the nearest provincial capitals to Wuhan, but we did not have the data on the prevalence of NAFLD in Changsha, China. Also, in most of the subgroups that were created according to the common comorbidities, no significant differences were found. However, the results did show certain trends. Univariate analysis indicated that non-elderly NAFLD patients had a higher incidence of severe events.

Nevertheless, after adjusting for gender, hypertension and BMI, the difference became statistically insignificant. This may be because of the small sample size and the high incidence of comorbidities.

Another limitation is that in the subgroup analysis on BMI, we only divided our patients into three groups. Overweight and obese patients were pooled together in one group (BMI ≥24 kg/m 2 ), due to the small number of obese patients (BMI ≥28 kg/m2). Finally, as this study was retrospective, data regarding abdominal adiposity was not available. Therefore, well-designed studies with larger sample sizes are still needed to more clearly demonstrate the association between NAFLD and the outcomes of COVID-19.

In summary, people with NAFLD may have a higher proportion of SARS-CoV-2 infection, with a higher rate of liver injury, as well as a higher incidence of severe COVID-19 in normal-weight patients. People who have NAFLD may need stronger protection and more aggressive treatment to decrease the risk of infection, reduce the chance of liver injury and improve the outcome.

However, due to the small sample size, especially for elderly patients, further studies with a larger sample size are required to confirm these findings.

Not available.

The authors confirm that there are no conflicts of interest. Abbreviation: NAFLD, non-alcoholic fatty liver disease.

Conceptualization (equal); Data curation (equal)

Formal analysis (equal)

Investigation (equal)

Resources (equal)

Writing-original draft (equal)

Writing-review & editing (equal)

Funding acquisition (equal); Investigation (equal)

Supervision (equal)

Validation (equal)

Chenfang Wu: Data curation (equal); Investigation (equal)

Supervision (equal)

Quan Zhang: Data curation (equal)

Investigation (equal)

Fang Wu: Formal analysis (equal)

Investigation (equal)

Bo Yu: Conceptualization (equal); Data curation (equal)

Siye Zhang: Data curation (equal)

Formal analysis (equal)

Chao Wu: Data curation (equal); Formal analysis (equal)

Writing-original draft (equal)

Yanjun Zhong: Conceptualization (equal); Data curation (equal); Formal analysis (equal)

Investigation (equal)

Resources (equal)

Supervision (equal)

Validation (equal)

Visualization (equal)

Writing-original draft (equal)

Writingreview & editing (equal)

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan, China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Chest Radiographic and CT Findings of the 2019 Novel Coronavirus Disease (COVID-19): Analysis of Nine Patients Treated in Korea

2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis

Liver injury in COVID-19: management and challenges

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Prevalence of nonalcoholic fatty liver disease in mainland of China: A meta-analysis of published studies

Epidemiology of non-alcoholic fatty liver disease in China

Epidemiology of alcoholic and nonalcoholic fatty liver disease in China

Epidemiological feature of NAFLD from 1999 to 2018 in China

Obesity and nonalcoholic fatty liver disease: current perspectives

Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics

Triglyceride Metabolism in the Liver

National health commission, National administration of traditional Chinese medicine. Diagnosis and treatment of new coronavirus pneumonia (trial sixth edition)

Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study

NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis

Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack

China Medical Treatment Expert Group for C. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

No evidence for an increased liver uptake of SARS-CoV-2 in metabolic associated fatty liver disease

COVID-19: Abnormal liver function tests

Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores

Mechanisms and implications of agerelated changes in the liver: nonalcoholic Fatty liver disease in the elderly

Influences of Gender and Age on the Prevalence and Complications of Nonalcoholic Fatty Liver Disease. Zhongguo Yi Xue Ke Xue Yuan Xue Bao Acta Academiae Medicinae Sinicae

Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients

Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States

Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies

New trends on obesity and NAFLD in Asia

Additional supporting information may be found in the online version of the article at the publisher's website.How to cite this article: Wang G, Wu S, Wu C, et al. Association between non-alcoholic fatty liver disease with the susceptibility and outcome of COVID-19: A retrospective study. J Cell Mol Med. 2021; 25:11212-11220. https://doi. org/10.1111/jcmm.17042